iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021

Rhea-AI Summary

iBio, Inc. (NYSEA:IBIO) will report its fiscal 2022 first quarter financial results after market close on November 15, 2021. The company, known for its sustainable, plant-based FastPharming Manufacturing System, will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss these results and provide a corporate update. Investors can access the live and archived webcast on the company's website. iBio focuses on developing biopharmaceuticals for treating cancers, fibrotic conditions, and infectious diseases.

Positive

• Scheduled webcast for discussing fiscal 2022 Q1 results indicates transparency and engagement with investors.

Negative

• None.

BRYAN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System^®, announced today that it will report its fiscal 2022 first quarter financial results after market close on Monday, November 15, 2021. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Company’s website at www.ibioinc.com under “News and Events” in the Investors section. The live call can be accessed by dialing (833) 672-0651 (domestic) or (929) 517-0227 (international) and referencing conference code: 7779281.

About iBio, Inc.

iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming System^® combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s wholly-owned subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services^TM for advanced recombinant protein design. For more information, visit www.ibioinc.com.

Contact:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com

FAQ

When will iBio report its fiscal 2022 first quarter results?

iBio will report its fiscal 2022 first quarter financial results after market close on November 15, 2021.

How can I access the iBio earnings call?

The iBio earnings call can be accessed by dialing (833) 672-0651 for domestic calls or (929) 517-0227 for international calls, referencing conference code 7779281.

What is the focus of iBio's business?

iBio develops next-generation biopharmaceuticals, including monoclonal antibodies and vaccines, primarily for cancers, fibrotic diseases, and infectious diseases.